SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

INOs FDA approval is prompting traders to speculate that the agency may be more receptive to rare-disease treatments, lifting attention on Capricor ahead of deramiocels FDA decision for Duchenne muscular dystrophy. The community is divided: some see the approval, recent data and launch-related hiring as encouraging signals, while others stress that CAPRs outcome is uncertain given prior FDA concerns and debate over the evidence.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure in a sharp semiconductor selloff as traders question whether heavy AI infrastructure spending will deliver sufficient returns, with weak Intel guidance and Amazons elevated capital spending adding to tech-sector jitters. The community is divided between warnings that AI-related investment and financing risks could prolong the decline and dip buyers pointing to strong demand and oversold conditions.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has put Precigens PAPZIMEOS in focus, prompting debate over the threat of new competition. Some traders worry about market share, while others argue Precigens first-mover advantage, commercial launch, and full approval temper the risk compared with Inovios accelerated approval.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A stronger-than-expected quarterly report, fueled by demand for Mounjaro and Zepbound and a higher full-year revenue outlook, is driving LLYs rally and analyst upgrades. Bullish traders point to continued obesity-drug growth, while skeptics flag the trimmed profit outlook and high valuation.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline significantly during 2027 has fueled a sharp selloff, raising concerns about pricing and CorMedixs largest revenue driver. Traders disagree over whether DaVitas preliminary outlook signals lasting pressure, pointing to CMSs more reassuring payment estimate and arguing the reaction may be excessive.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration sales from Dupixent, are driving attention. Traders are broadly bullish on the sharp rally and breakout, while some are weighing whether the gains can be sustained.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is drawing attention after a sharp selloff tied to Brazils election results and broader weakness in Brazilian-linked stocks. Traders disagree over whether political and market risks signal further downside or create a buying opportunity, with some pointing to the companys continued growth ahead of earnings.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZenecas stronger-than-expected quarterly results and cost-savings plan to support drug development are driving attention, alongside CEO optimism about its pipeline. Traders are reacting to the sharp rise and move above the 200-day average with broadly bullish commentary.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs quarterly results beat estimates, but declining user activity and a forecast for lower fourth-quarter bookings have driven a sharp selloff. Traders are largely bearish over slowing growth and monetization, while some view the drop as an overreaction and a buying opportunity.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas earnings beat and raised outlook, alongside its positioning as an identity-security layer for AI agents, have fueled a sharp cybersecurity-led rally. Traders are divided over whether demand can justify the valuation, with some taking profits or betting on a pullback after the run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CVB Financial (CVBF) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

CVB Financial (CVBF) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for CVB Financial (CVBF) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CVB Financial (CVBF) Lags Q3 Earnings Estimates

CVB Financial (CVBF) delivered earnings and revenue surprises of -2.22% and +1.10%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

RBB (RBB) Q3 Earnings and Revenues Surpass Estimates

RBB (RBB) delivered earnings and revenue surprises of +29.83% and +8.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Bay Commercial Bank (BCML) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Bay Commercial Bank (BCML) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVB Financial (CVBF) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CVB Financial (CVBF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVB Financial Director Mike Maddox Buys 10,000 Shares

CVB Financial Director Mike Maddox Buys 10,000 Shares...

CVB Financial (CVBF) Upgraded to Buy: Here's What You Should Know

CVB Financial (CVBF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Compared to Estimates, CVB Financial (CVBF) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for CVB Financial (CVBF) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

CVB Financial (CVBF) Q2 Earnings Surpass Estimates

CVB Financial (CVBF) delivered earnings and revenue surprises of +4.76% and -2.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of $0.48 up 26.32% YoY
• Reported revenue of $191.74M up 49.12% YoY

CVB Financial Corp. reported a $439M pre-tax AFS unrealized loss that widened from June, a lower noninterest-bearing deposit mix year over year, and disclosed Heritage integration and retention risks.

CVB Financial Corp. reported higher Q3 2026 net earnings and diluted EPS than Q2, expanded net interest margin to 3.89%, and posted lower adjusted efficiency ratio and acquisition-related expenses.

CVB Financial Corp. is a bank holding company, which engages in the provision of relationship-based banking products, services, and solutions for small to mid-sized companies, real estate investors, non-profit organizations, professionals, and other individuals through its subsidiary, Citizens Business Bank. Its products include loans for commercial businesses, commercial real estate, multi-family, construction, land, dairy and livestock and agribusiness, consumer and government-guaranteed small business loans. The company was founded by George A. Borba on April 27, 1981 and is headquartered in Ontario, CA.

CVB Financial Corp.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.47	--	--	N/A
Q3 '26	$0.41	$0.44	6.88%	BEAT
Q2 '26	$0.30	$0.29	-2.68%	MISSED
Q1 '26	$0.37	$0.38	1.79%	BEAT
Q4 '25	$0.39	$0.40	2.13%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

CVBF Earnings

Latest Earnings Results: Q3 '26

Historical Earnings